These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30196384)

  • 21. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
    Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
    Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
    Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
    Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
    Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
    Chakraborty AK; Zerillo C; DiGiovanna MP
    Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.
    Kramer-Marek G; Gijsen M; Kiesewetter DO; Bennett R; Roxanis I; Zielinski R; Kong A; Capala J
    J Nucl Med; 2012 Apr; 53(4):629-37. PubMed ID: 22410461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
    Bernadou G; Campone M; Merlin JL; Gouilleux-Gruart V; Bachelot T; Lokiec F; Rezai K; Arnedos M; Diéras V; Jimenez M; Paintaud G; Ternant D
    Br J Clin Pharmacol; 2016 May; 81(5):941-8. PubMed ID: 26714164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
    Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
    Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
    Church DN; Bahl A; Jones A; Price CG
    J Neurooncol; 2006 Sep; 79(3):289-92. PubMed ID: 16821088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of Trastuzumab-HER2 Engagement In Vitro and In Vivo.
    Rudkouskaya A; Smith JT; Intes X; Barroso M
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33348564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
    Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G
    MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
    Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
    Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
    You Y; Xu Z; Chen Y
    Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.